End-of-day quote
Shanghai S.E.
06:00:00 2024-05-20 pm EDT
|
5-day change
|
1st Jan Change
|
5.59
CNY
|
-3.79%
|
|
-5.73%
|
-37.82%
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
9,400
|
5,820
|
3,619
|
-
|
-
|
Enterprise Value (EV)
1 |
9,400
|
5,820
|
3,619
|
3,619
|
3,619
|
P/E ratio
|
230
x
|
-45.2
x
|
-31.1
x
|
168
x
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
32.3
x
|
27.3
x
|
10.1
x
|
7.73
x
|
9.76
x
|
EV / Revenue
|
32.3
x
|
27.3
x
|
10.1
x
|
7.73
x
|
9.76
x
|
EV / EBITDA
|
143
x
|
-48.7
x
|
56.6
x
|
30.3
x
|
-
|
EV / FCF
|
-
|
-9.14
x
|
-17
x
|
-22.6
x
|
113
x
|
FCF Yield
|
-
|
-10.9%
|
-5.89%
|
-4.42%
|
0.88%
|
Price to Book
|
4.33
x
|
2.82
x
|
1.86
x
|
1.42
x
|
-
|
Nbr of stocks (in thousands)
|
641,146
|
647,433
|
647,433
|
-
|
-
|
Reference price
2 |
14.66
|
8.990
|
5.590
|
5.590
|
5.590
|
Announcement Date
|
2/23/23
|
2/23/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
291.3
|
213
|
359.4
|
468.2
|
371
|
EBITDA
1 |
-
|
65.77
|
-119.4
|
63.91
|
119.4
|
-
|
EBIT
1 |
-
|
41.71
|
-156.1
|
-123
|
26.33
|
-
|
Operating Margin
|
-
|
14.32%
|
-73.26%
|
-34.22%
|
5.62%
|
-
|
Earnings before Tax (EBT)
1 |
-
|
41.62
|
-156.2
|
-123
|
17.38
|
-
|
Net income
1 |
54.26
|
39.03
|
-128
|
-116
|
19.88
|
-
|
Net margin
|
-
|
13.4%
|
-60.09%
|
-32.28%
|
4.25%
|
-
|
EPS
2 |
0.1077
|
0.0638
|
-0.1990
|
-0.1800
|
0.0333
|
-
|
Free Cash Flow
1 |
-
|
-
|
-637
|
-213
|
-160
|
32
|
FCF margin
|
-
|
-
|
-299.01%
|
-59.27%
|
-34.18%
|
8.63%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/2/22
|
2/23/23
|
2/23/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-637
|
-213
|
-160
|
32
|
ROE (net income / shareholders' equity)
|
-
|
2.12%
|
-6.06%
|
-0.01%
|
1.63%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
1.75%
|
-4.98%
|
-4.5%
|
0.4%
|
-
|
Assets
1 |
-
|
2,233
|
2,573
|
2,578
|
4,928
|
-
|
Book Value Per Share
2 |
-
|
3.390
|
3.190
|
3.000
|
3.930
|
-
|
Cash Flow per Share
2 |
-
|
0.0300
|
-0.1400
|
-0.1600
|
0.1600
|
-
|
Capex
1 |
-
|
484
|
547
|
103
|
74
|
38
|
Capex / Sales
|
-
|
166.29%
|
256.71%
|
28.66%
|
15.81%
|
10.24%
|
Announcement Date
|
3/2/22
|
2/23/23
|
2/23/24
|
-
|
-
|
-
|
Last Close Price
5.59
CNY Average target price
8.2
CNY Spread / Average Target +46.69% Consensus |
1st Jan change
|
Capi.
|
---|
| -37.82% | 500M | | +37.78% | 723B | | +31.70% | 598B | | -3.51% | 364B | | +19.94% | 331B | | +5.14% | 288B | | +15.77% | 244B | | +9.78% | 210B | | -5.15% | 208B | | +9.32% | 169B |
Other Pharmaceuticals
|